Microvascular Therapeutics (MVT), LLC, a privately-held Tucson-based biotechnology company, has licensed a patent from Triangle Biotechnology, Inc, entitled, "Formulation of acoustically activatable particles having low vaporization energy and methods for using same" (U.S. Patent No. 9,427,410, issued August 30th, 2016). Founders of MVT also previously developed Definity®, the world’s #1 selling ultrasound contrast agent. MVT is currently developing a new, improved ultrasound contrast agent referred to as MVT-100 via the 505(b)(2) pathway. In addition, MVT is developing targeted agents for molecular ultrasound imaging and theranostics to potentially treat diseases less invasively and more effectively using nanotechnology with ultrasound. Licensing the patent from Triangle Biotechnology, positions MVT to accelerate towards its vision of developing targeted therapy with ultrasound and nanotechnology
- MVT